Free Trial
Investment Research Tools for the A.I. EraStart My Trial

PureTech Health (LON:PRTC) Stock Price Up 14.2% - Here's What Happened

Written by MarketBeat
Updated September 22, 2025
PureTech Health logo with Medical background

Key Points

  • PureTech Health plc's stock rose by 14.2%, trading at GBX 121.50 ($1.64) after reaching a high of GBX 123.80 ($1.67) on Saturday, with trading volume significantly up by 1,053% compared to its average.
  • The company's market cap stands at £293.65 million, with a price-to-earnings ratio of 714.71 and a relatively high debt-to-equity ratio of 45.82.
  • Insider Bharatt Chowrira purchased 167,739 shares at £1 per share, indicating confidence from within the company as insiders collectively own 13.13% of the stock.
  • Five stocks we like better than PureTech Health.

PureTech Health plc (LON:PRTC - Get Free Report) was up 14.2% during trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during mid-day trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Price Performance

The company has a market capitalization of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The stock has a fifty day simple moving average of GBX 129.31 and a 200-day simple moving average of GBX 129.65.

Insider Activity

In related news, insider Bharatt Chowrira bought 167,739 shares of the business's stock in a transaction on Thursday, July 3rd. The stock was acquired at an average cost of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is owned by company insiders.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Recommended Stories

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover
Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.